Wall Street Sees 84% Upside in Hims & Hers Despite This Month's 48% Selloff

Novo Nordisk sued Hims & Hers for patent infringement over compounded semaglutide, forcing the company to cancel its Wegovy alternative weight-loss product. The lawsuit, combined with FDA action against Hims' $49 compounded weight-loss pill citing quality and safety violations, triggered a 48% stock selloff. The HHS matter has been referred to the Department of Justice. Management hopes to resolve the Novo Nordisk dispute through partnership to offer branded GLP-1 products.